Free Cash Flow Chart

Historical Free Cash Flow Data

View and export this data back to 2020. Start Trial.
Date Value
September 30, 2026 -314.48M
June 30, 2026 -354.26M
March 31, 2026 -328.08M
December 31, 2025 -380.44M
September 30, 2025 -450.20M
June 30, 2025 -396.38M
March 31, 2025 -401.06M
December 31, 2024 -376.22M
September 30, 2024 -335.64M
June 30, 2024 -345.60M
March 31, 2024 -330.63M
December 31, 2023 -300.33M
Date Value
September 30, 2023 -276.56M
June 30, 2023 -265.92M
March 31, 2023 -272.58M
December 31, 2022 -120.88M
September 30, 2022 -133.78M
June 30, 2022 -113.43M
March 31, 2022 -75.20M
December 31, 2021 -198.41M
September 30, 2021 -128.81M
June 30, 2021 -106.34M
March 31, 2021 -83.80M
December 31, 2020 -52.13M

Free Cash Flow Range, Past 5 Years

View Free Cash Flow Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow Benchmarks

View Free Cash Flow Benchmarks
Start Trial
Absci Corp. -112.46M
Editas Medicine, Inc. -110.46M
Twist Bioscience Corp. -95.96M
Beam Therapeutics, Inc. -398.24M
AbbVie, Inc. 18.87B